Caitlin Costello

4.9k total citations
64 papers, 910 citations indexed

About

Caitlin Costello is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Caitlin Costello has authored 64 papers receiving a total of 910 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 32 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Caitlin Costello's work include Multiple Myeloma Research and Treatments (32 papers), CAR-T cell therapy research (17 papers) and Protein Degradation and Inhibitors (15 papers). Caitlin Costello is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), CAR-T cell therapy research (17 papers) and Protein Degradation and Inhibitors (15 papers). Caitlin Costello collaborates with scholars based in United States, Canada and Italy. Caitlin Costello's co-authors include Jesús G. Berdeja, Matthew A. Spear, Tara Gregory, Devon J. Shedlock, Krina K. Patel, Adam D. Cohen, Eric Ostertag, Nizar J. Bahlis, Melhem Solh and Alexander M. Lesokhin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Caitlin Costello

54 papers receiving 891 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Caitlin Costello United States 17 519 463 455 157 140 64 910
Sherilyn A. Tuazon United States 10 494 1.0× 476 1.0× 517 1.1× 128 0.8× 118 0.8× 27 941
Abdul Hamid Bazarbachi United States 14 479 0.9× 388 0.8× 550 1.2× 153 1.0× 61 0.4× 30 878
Khalid Mezzi United States 12 426 0.8× 411 0.9× 499 1.1× 142 0.9× 100 0.7× 26 788
Hervé Dombret France 9 567 1.1× 281 0.6× 417 0.9× 190 1.2× 81 0.6× 14 1.1k
R N Sridhara United States 5 461 0.9× 343 0.7× 311 0.7× 109 0.7× 272 1.9× 8 974
Anna van Rhenen Netherlands 13 408 0.8× 404 0.9× 696 1.5× 300 1.9× 42 0.3× 39 1.2k
Shebli Atrash United States 13 454 0.9× 403 0.9× 521 1.1× 112 0.7× 73 0.5× 119 752
FO Smith United States 9 281 0.5× 426 0.9× 596 1.3× 173 1.1× 189 1.4× 15 1.1k
Thomas G. Martin United States 15 534 1.0× 446 1.0× 593 1.3× 138 0.9× 150 1.1× 79 946

Countries citing papers authored by Caitlin Costello

Since Specialization
Citations

This map shows the geographic impact of Caitlin Costello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caitlin Costello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caitlin Costello more than expected).

Fields of papers citing papers by Caitlin Costello

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caitlin Costello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caitlin Costello. The network helps show where Caitlin Costello may publish in the future.

Co-authorship network of co-authors of Caitlin Costello

This figure shows the co-authorship network connecting the top 25 collaborators of Caitlin Costello. A scholar is included among the top collaborators of Caitlin Costello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caitlin Costello. Caitlin Costello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Silver, Elisabeth R., et al.. (2025). Association of Pre-Transplant Daratumumab Use with Infection in AL Amyloidosis Heart Transplant Recipients. The Journal of Heart and Lung Transplantation. 44(4). S642–S642.
3.
Dholaria, Bhagirathbhai, Mehmet H. Kocoglu, Leyla Shune, et al.. (2025). A Phase 1 Study of P-BCMA-ALLO1, a Non-Viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM): Results from Optimized Lymphodepletion Cohort (Arm C). Transplantation and Cellular Therapy. 31(2). S38–S38.
4.
Koura, Divya, Aaron M. Goodman, Caitlin Costello, et al.. (2025). A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept. Blood Advances. 9(16). 4336–4344.
5.
Rosenberg, Aaron S., Emanual Maverakis, Caitlin Costello, et al.. (2025). Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis. PubMed. 2(3). 100067–100067.
6.
7.
Costello, Caitlin, et al.. (2024). Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience.. Journal of Clinical Oncology. 42(16_suppl). e19504–e19504. 2 indexed citations
8.
Brubaker, Aleah L., Marcus A. Urey, Justin Parekh, et al.. (2023). Heart-liver-kidney transplantation for AL amyloidosis using normothermic recovery and storage from a donor following circulatory death: Short-term outcome in a first-in-world experience. American Journal of Transplantation. 23(2). 291–293. 6 indexed citations
9.
Bahlis, Nizar J., Caitlin Costello, Noopur Raje, et al.. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature Medicine. 29(10). 2570–2576. 76 indexed citations
10.
Lo, Mimi, Rebecca Young, Ila M. Saunders, et al.. (2023). Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma. Journal of Oncology Pharmacy Practice. 29(7). 1715–1724. 1 indexed citations
11.
Lonial, Sagar, et al.. (2023). Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23(11). 815–824. 7 indexed citations
12.
Liu, Lin, Minya Pu, Emily Pittman, et al.. (2022). Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results.. Journal of Clinical Oncology. 40(16_suppl). 8041–8041. 2 indexed citations
13.
Zhou, Tianyuan, Elisa Lazzari, Luisa Ladel, et al.. (2021). Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell stem cell. 28(4). 623–636.e9. 38 indexed citations
14.
Costello, Caitlin, et al.. (2021). Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells. STAR Protocols. 2(2). 100565–100565. 3 indexed citations
15.
Costello, Caitlin, et al.. (2020). Supportive Care in Multiple Myeloma. Current Hematologic Malignancy Reports. 15(2). 56–61. 16 indexed citations
16.
17.
Poh, Christina, Paul Frankel, Christopher Ruel, et al.. (2019). Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 134(Supplement_1). 760–760. 25 indexed citations
18.
Costello, Caitlin, Tara Gregory, Syed Abbas Ali, et al.. (2019). Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME). Blood. 134(Supplement_1). 3184–3184. 43 indexed citations
19.
Lazzari, Elisa, Nathaniel P. Delos Santos, Amber Miller, et al.. (2017). Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nature Communications. 8(1). 1922–1922. 87 indexed citations
20.
Holman, Peter, Caitlin Costello, Margarida Magalhaes‐Silverman, et al.. (2011). Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 18(2). 257–264. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sherilyn A. Tuazon Breakdown of academic impact, for papers by Abdul Hamid Bazarbachi Breakdown of academic impact, for papers by Khalid Mezzi Breakdown of academic impact, for papers by Hervé Dombret Breakdown of academic impact, for papers by R N Sridhara Breakdown of academic impact, for papers by Anna van Rhenen Breakdown of academic impact, for papers by Shebli Atrash Breakdown of academic impact, for papers by FO Smith Breakdown of academic impact, for papers by Thomas G. Martin
Rankless by CCL
2026